Summary: A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Top Publications

  1. Ben Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475-6 pubmed publisher
  2. Murphy G, Schmidt Martin D, Hynes B, Harney S. Systemic listeriosis with adalimumab therapy. J Clin Rheumatol. 2009;15:369-70 pubmed publisher
  3. Burmester G, Matucci Cerinic M, Mariette X, Navarro Blasco F, Kary S, Unnebrink K, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014;16:R24 pubmed publisher
    ..rheumatoid arthritis who had failed at least one disease-modifying anti-rheumatic drug (DMARD) were treated with adalimumab (ADA) in the ReAct study with the option to continue treatment for 5 years in ReAlise...
  4. Arnoult C, Brachet G, Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, et al. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti-TNF-? Antibodies after a Single Injection in Mice. J Immunol. 2017;199:418-424 pubmed publisher
    The immunogenicity of infliximab and adalimumab is a major concern because patients may develop Abs also called antidrug Abs (ADA), directed against these anti-TNF-? Abs after just a few weeks of treatment...
  5. Zamora Atenza C, Diaz Torne C, Geli C, Diaz Lopez C, Ortiz M, Moya P, et al. Adalimumab regulates intracellular TNF? production in patients with rheumatoid arthritis. Arthritis Res Ther. 2014;16:R153 pubmed publisher
    b>Adalimumab is a fully human anti-tumor necrosis factor ? (anti-TNF?) monoclonal antibody that specifically blocks the interaction of TNF? with its receptors. It binds both soluble and transmembrane TNF?...
  6. Rahman N, Healy C, Flint S, Stassen L. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. J Clin Rheumatol. 2010;16:197-9 pubmed publisher
  7. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?. Arthritis Rheum. 2011;63:867-70 pubmed publisher
  8. Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle Deschner J, Tzaribacev N, et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14:R230 pubmed publisher
    While adalimumab is licensed for ankylosing spondylitis (AS), open uncontrolled studies suggest therapeutic efficacy of TNF-inhibitors in juvenile onset AS (JoAS)...
  9. Cohen S, Genovese M, Choy E, Perez Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76:1679-1687 pubmed publisher
    ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar...

More Information


  1. Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013;15:R135 pubmed publisher
    Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated...
  2. Moots R, Xavier R, Mok C, Rahman M, Tsai W, Al Maini M, et al. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE. 2017;12:e0175207 pubmed publisher
    ..antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, ..
  3. Jiang Y, Lin O, Sinha S. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci. 2017;62:1597-1606 pubmed publisher
    ..The majority of providers are either uncertain about or actively avoid use of anti-TNF? medications for those with HF. The risks and benefits of anti-TNF? use in HF patients must be investigated further. ..
  4. Paramarta J, Baeten D. Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther. 2014;16:R160 pubmed publisher
    ..well as to relapse upon treatment discontinuation, in peripheral spondyloarthritis (pSpA) patients treated with adalimumab. The study included 26 pSpA patients treated with adalimumab for either 12 weeks (n = 12) or 24 weeks (n = 14) ..
  5. Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh S, Soroush M, Ahmadzadeh A, et al. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid. Arthritis Res Ther. 2017;19:168 pubmed publisher
    This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product (Humira®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA)...
  6. Jemec G. Hidradenitis suppurativa and immune dysregulation. Br J Dermatol. 2012;166:237-8 pubmed publisher
  7. Gonzalo Garijo M, Rodríguez Nevado I, Pérez Calderón R, Sánchez Vega S, Pérez Rangel I. Severe cutaneous reaction and fever due to adalimumab. Ann Allergy Asthma Immunol. 2010;105:490-1 pubmed publisher
  8. Cury D, Moss A, Elias G, Nakao A. Adalimumab for cutaneous metastatic Crohn's disease. Inflamm Bowel Dis. 2010;16:723-4 pubmed publisher
  9. Durham L, Taams L, Kirkham B. Psoriatic arthritis. Br J Hosp Med (Lond). 2016;77:C102-8 pubmed publisher
  10. Singh J, Hossain A, Mudano A, Tanjong Ghogomu E, Suarez Almazor M, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;5:CD012657 pubmed publisher
    ..To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule ..
  11. Shivaji U, Awasthi A, Aherne R. Cutaneous Vasculitis Caused by Anti-Tumor Necrosis Factor Therapy: A Case Report. Clin Gastroenterol Hepatol. 2016;14:e1-2 pubmed publisher
  12. Bakkour W, Coulson I, Sahasrabudhe N. Adalimumab-induced medium-sized vessel vasculitis. Clin Exp Dermatol. 2012;37:562-4 pubmed publisher
  13. Ruiz Argüello B, del Agua A, Torres N, Monasterio A, Martinez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med. 2013;51:e287-9 pubmed publisher
  14. Weiß A, Song I, Haibel H, Listing J, Sieper J. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther. 2014;16:R35 pubmed publisher
    ..PRO) and objective inflammation in patients with axial spondylarthritis (SpA) treated with etanercept (ETA) or adalimumab (ADA)...
  15. Cavallaro F, Duca L, Pisani L, Rigolini R, Spina L, Tontini G, et al. Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Can J Gastroenterol Hepatol. 2017;2017:6843976 pubmed publisher
    ..This effect appears to be related to the modulation of the cytokine network and specifically IL-6 leading to a relevant decrease of hepcidin, a master regulator of ACD. ..
  16. Kennedy W, Simón J, Offutt C, Horn P, Herman A, Townsend M, et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res Ther. 2014;16:467 pubmed publisher
    ..head-to-head, active- and placebo-controlled trial examined the safety and efficacy of pateclizumab compared to adalimumab in RA patients with an inadequate response to disease-modifying antirheumatic drugs (DMARD-IR)...
  17. Ward M, Thwaites P, Beswick L, Hogg J, Rosella G, Van Langenberg D, et al. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther. 2017;45:1135-1145 pubmed publisher
    Whether therapeutic drug monitoring for adalimumab needs to be performed at trough has not been defined.
  18. Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, et al. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Res Ther. 2017;19:56 pubmed publisher
    This study was conducted to evaluate the feasibility of long-term adalimumab (ADA) discontinuation after achievement of low disease activity (LDA) in Japanese patients with early rheumatoid arthritis (RA) and to identify predictors of LDA ..
  19. Mease P, Hall S, Fitzgerald O, van der Heijde D, Merola J, Avila Zapata F, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377:1537-1550 pubmed publisher
    ..We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs)...
  20. Schoffelen T, Kampschreur L, van Roeden S, Wever P, den Broeder A, Nabuurs Franssen M, et al. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNF? therapy. Ann Rheum Dis. 2014;73:1436-8 pubmed publisher
  21. Chara L, Sánchez Atrio A, Perez A, Cuende E, Albarrán F, Turrión A, et al. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res Ther. 2012;14:R175 pubmed publisher
    ..MTX) non-responder patients with RA, and to determine their value in predicting the clinical response to adalimumab plus MTX treatment...
  22. Krieckaert C, Nurmohamed M, Wolbink G. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914-5 pubmed publisher
  23. Mackey A, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-8 pubmed
  24. Danese S, Fiorino G, Peyrin Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704-11 pubmed publisher
    ..placebo-controlled trials that were rated as low risk of bias and showed that all biological agents (adalimumab, golimumab, infliximab, and vedolizumab) resulted in more clinical responses, clinical remissions, and mucosal ..
  25. de Jong T, Vosslamber S, Verweij C. Moving towards personalized medicine in rheumatoid arthritis. Arthritis Res Ther. 2014;16:110 pubmed
    ..These observations assign biological pathways associated with response outcome and provide evidence for the existence of systemic,easy-to-measure predictive biomarkers for clinical benefit of these biologics. ..
  26. Vermeer M, Kuper H, Bernelot Moens H, Hoekstra M, Posthumus M, van Riel P, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther. 2012;14:R254 pubmed publisher
    ..The recommendations regarding T2T were successfully implemented and high adherence was observed. This demonstrates that a T2T strategy is feasible in RA in daily clinical practice. ..
  27. Seo H, Ye B, Song E, Lee S, Chang K, Lee H, et al. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci. 2017;62:2882-2893 pubmed publisher
    Large-scale studies regarding the long-term outcomes of adalimumab (ADA) treatment in Asian patients with Crohn's disease (CD) are still scarce...
  28. Desbois A, Vallet H, Domont F, Comarmond C, Cacoub P, Saadoun D. Management of severe complications in Behçet's disease with TNF inhibitors. Expert Opin Biol Ther. 2017;17:853-859 pubmed publisher
    ..Experts in the field do recommend the use of anti-TNF agents (either infliximab or adalimumab) as a first-line therapy in severe posterior uveitis in BD and now use anti-TNF? treatment in BD-associated life ..
  29. Maksymowych W, Russell A, Chiu P, Yan A, Jones N, Clare T, et al. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther. 2012;14:R206 pubmed publisher
    ..We conducted an open-label evaluation of adalimumab over 12 weeks in 20 patients with OA of the knee and evidence of effusion clinically...
  30. Ibrahim F, Lorente Cánovas B, Doré C, Bosworth A, Ma M, Galloway J, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?. Rheumatology (Oxford). 2017;56:2004-2014 pubmed publisher
    ..The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response...
  31. Buchner A, Lichtenstein G. Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?. Am J Gastroenterol. 2017;112:1593-1595 pubmed publisher
    ..The study by Khanna et al. evaluated the responsiveness of the SES-CD and CDEIS using data from a trial of adalimumab. The study used appropriate statistical methods to quantify responsiveness of the indices as assessed by blinded ..
  32. Baraliakos X, Sieper J, Chen S, Pangan A, Anderson J. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. Rheumatology (Oxford). 2017;56:1162-1166 pubmed publisher
    ..Patients with non-radiographic axSpA (nr-axSpA) were randomized to receive adalimumab 40 mg every other week or placebo for 12 weeks in ABILITY-1...
  33. Bouman C, van Herwaarden N, van den Hoogen F, Fransen J, van Vollenhoven R, Bijlsma J, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 2017;76:1716-1722 pubmed publisher
    ..Safety and efficacy of disease activity guided TNFi DR in RA are maintained up to 3?years, with a large reduction in TNFi use, but no other benefits. Implementation of DR would vastly improve the cost-effective use of TNFi. ..
  34. Dennis G, Holweg C, Kummerfeld S, Choy D, Setiadi A, Hackney J, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16:R90 pubmed
    ..analysis compared with therapeutic outcome at week 24 in serum samples from 198 patients from the ADACTA (ADalimumab ACTemrA) phase 4 trial of tocilizumab (anti-IL-6R) monotherapy versus adalimumab (anti-TNF?) monotherapy...
  35. Ramanan A, Dick A, Jones A, McKay A, Williamson P, Compeyrot Lacassagne S, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376:1637-1646 pubmed publisher
    b>Adalimumab, a fully human anti-tumor necrosis factor ? monoclonal antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested the efficacy of adalimumab in the treatment of JIA-associated uveitis...
  36. Klingberg E, Strid H, Ståhl A, Deminger A, Carlsten H, Ohman L, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017;19:21 pubmed publisher
    ..We propose that fecal calprotectin may be a potential biomarker to identify patients with AS at risk of developing IBD. identifier: NCT00858819 . Registered 9 March 2009. Last updated 28 May 2015. ..
  37. Miller F, Jones C, Clarke L, Lin Z, Adams D, Koltun W. Successful use of adalimumab in treating cutaneous metastatic Crohn's disease: report of a case. Inflamm Bowel Dis. 2009;15:1611-2 pubmed publisher
  38. Callejas Rubio J, Sanchez Cano D, Ríos Fernández R, Ortego Centeno N. [Treatment of Behçet's disease with adalimumab]. Med Clin (Barc). 2008;131:438-9 pubmed
  39. Balint A, Rutka M, Végh Z, Kürti Z, Gecse K, Banai J, et al. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opin Drug Saf. 2017;16:885-890 pubmed publisher
    ..CT-P13 therapy had to be stopped in 17 patients who developed infusion reaction and was switched to adalimumab in 12 patients. However in 39...
  40. Rendas Baum R, Kosinski M, Singh A, Mebus C, Wilkinson B, Wallenstein G. Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials. Rheumatology (Oxford). 2017;56:1386-1394 pubmed publisher
    ..1115) with inadequate response to MTX or TNF inhibitors (TNFi) receiving tofacitinib 5 or 10 mg twice daily, adalimumab (one study only) or placebo, in combination with MTX...
  41. Kaltsonoudis E, Zikou A, Voulgari P, Konitsiotis S, Argyropoulou M, Drosos A. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125 pubmed publisher
    ..The aim was to investigate the frequency of neurological adverse events in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA) treated with tumor necrosis factor (TNF) ? antagonists...
  42. Miyake T, Ogawa E, Mikoshiba A, Kobayashi A, Hosoe H, Kashiwabara S, et al. Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. J Dermatol Sci. 2012;68:199-202 pubmed publisher
  43. Triantafillidis J, Malgarinos G. Severe psoriasis preceding diagnosis of large bowel Crohn's disease for 15 years. J Crohns Colitis. 2013;7:e80 pubmed publisher
  44. Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017;17:879-886 pubmed publisher
    ..Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis...
  45. Tanaka M, Sakai R, Koike R, Harigai M. Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents. J Rheumatol. 2015;42:1726-8 pubmed publisher
  46. Paramarta J, Heijda T, Baeten D. Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis. Ann Rheum Dis. 2013;72:1581-2 pubmed publisher
  47. Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, et al. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol. 2012;41:490-1 pubmed publisher
  48. Otake H, Matsumoto S, Mashima H. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study. Medicine (Baltimore). 2017;96:e6635 pubmed publisher
    ..receiving the same biologic type for at least 1 year were divided into 2 groups: infliximab (IFX) (n?=?39) and adalimumab (ADA) (n?=?29). Clinical courses were compared at biologic introduction and at 1 year...
  49. Chiricozzi A, Cannizzaro M, Salandri G, Marinari B, Pitocco R, Dattola A, et al. Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy. J Eur Acad Dermatol Venereol. 2016;30:e128-e129 pubmed publisher
  50. Null K, Xu Y, Pasquale M, Su C, Marren A, Harnett J, et al. Ulcerative Colitis Treatment Patterns and Cost of Care. Value Health. 2017;20:752-761 pubmed publisher
    ..patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ..
  51. Mizoshita T, Katano T, Tanida S, Hirano A, Miyaki T, Ozeki K, et al. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore). 2017;96:e7800 pubmed publisher
    There have been few reports on 2 tumor necrosis factor alpha inhibitors, infliximab and adalimumab, with respect to patient preference and efficacy in ulcerative colitis (UC)...
  52. Uhlig T, Goll G. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford). 2017;56:iv49-iv62 pubmed publisher
    ..Additional ongoing studies and registries may help to optimize the process of switching, and different funding models are examining the optimal mechanisms to ensure effective uptake of these new treatments. ..
  53. Woodman I. Rheumatoid arthritis: Optimizing treatment strategies in early RA. Nat Rev Rheumatol. 2013;9:695 pubmed publisher